Brenig Therapeutics Unveils Superior Safety Profile of LRRK2 Inhibitor BT-0267 with Exceptional CSF/Plasma Ratio at Future of Parkinson's Disease Conference
04 Dec 2023
Clinical Study
SAN DIEGO, Dec. 4, 2023 /PRNewswire/ -- Brenig Therapeutics, a portfolio company of Torrey Pines Investments, OrbiMed Advisors, and BioGeneration Ventures, announces new data on its LRRK2 inhibitorLRRK2 inhibitor drug candidate, BT-0267. The results were unveiled at the prestigious Future of Parkinson's Disease Conference.
LRRK2, recognized as a crucial drug target in Parkinson's disease, plays a major role in the pathogenesis of the condition. Inhibiting LRRK2 activity has emerged as a promising disease-modifying therapeutic strategy, and several drug candidates have achieved clinical status.
The BT-0267 candidate has an efficient blood-brain barrier penetration while minimized peripheral exposure as well as has a superior overall safety profile. The presented data highlighted the in vivo efficacy of BT-0267 in brain and no visible lung and kidney morphological changes compared to other LRRK2 inhibitorLRRK2 inhibitor candidates. Additionally, BT-0267 has an outstanding cerebrospinal fluid (CSF)/unbound plasma ratio in non-human primates, exhibits a remarkable 1000x selectivity against other kinases, and >500x selectivity against other targets from the safety panel, providing indicators of its best-in-class safety profile.
Dr. Alexei Pushechnikov, Head of Chemistry and CTO at Brenig Therapeutics, remarked, "Achieving an outstanding CSF/plasma ratio for BT-0267 is in line with our rational design strategy to reduce potential lung and kidney toxicity effects in our LRRK2 inhibition program."
About Brenig Therapeutics
Brenig Therapeutics, a portfolio company of OrbiMed Advisors, Torrey Pines Investments, and BioGeneration Ventures, focuses on developing innovative therapies for neurodegenerative diseases. The company's pipeline includes BT-0267, a best-in-class LRRK2 inhibitorLRRK2 inhibitor with a superior safety profile, currently advancing towards clinical development for Parkinson's disease.
For further information, contact:
Dr. Vasily Kazey
Venture Partner
vkazey@torreypinesinv.com
SOURCE Brenig Therapeutics Inc
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.